PharmaCyte Biotech (PMCB) Competitors $1.27 +0.07 (+5.83%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. COEP, OSTX, ALGS, NRXP, MRNS, LTRN, LVTX, AKTX, ALXO, and ALLKShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Coeptis Therapeutics (COEP), OS Therapies (OSTX), Aligos Therapeutics (ALGS), NRx Pharmaceuticals (NRXP), Marinus Pharmaceuticals (MRNS), Lantern Pharma (LTRN), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), ALX Oncology (ALXO), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. Coeptis Therapeutics OS Therapies Aligos Therapeutics NRx Pharmaceuticals Marinus Pharmaceuticals Lantern Pharma LAVA Therapeutics Akari Therapeutics ALX Oncology Allakos PharmaCyte Biotech (NASDAQ:PMCB) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Is PMCB or COEP more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 0.76% 0.45% Coeptis Therapeutics N/A -1,094.50%-219.97% Do analysts rate PMCB or COEP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, PMCB or COEP? PharmaCyte Biotech has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PMCB or COEP? 34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 10.2% of PharmaCyte Biotech shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in PMCB or COEP? Coeptis Therapeutics received 5 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/ACoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Does the media refer more to PMCB or COEP? In the previous week, PharmaCyte Biotech and PharmaCyte Biotech both had 2 articles in the media. PharmaCyte Biotech's average media sentiment score of 1.44 beat Coeptis Therapeutics' score of 0.44 indicating that PharmaCyte Biotech is being referred to more favorably in the media. Company Overall Sentiment PharmaCyte Biotech Positive Coeptis Therapeutics Neutral Which has better earnings & valuation, PMCB or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.741.72Coeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.61 SummaryPharmaCyte Biotech beats Coeptis Therapeutics on 8 of the 11 factors compared between the two stocks. Remove Ads Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.72M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.33%P/E Ratio2.4031.0021.8317.81Price / SalesN/A441.21379.4694.58Price / CashN/A168.6838.1534.64Price / Book0.393.476.454.00Net Income$330,000.00-$72.06M$3.20B$247.23M7 Day Performance7.17%9.27%6.60%7.26%1 Month Performance-19.62%-17.02%-8.50%-6.26%1 Year Performance-39.81%-29.23%10.33%-0.18% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech2.4443 of 5 stars$1.27+5.8%N/A-46.2%$8.72MN/A2.404Short Interest ↓Gap DownCOEPCoeptis Therapeutics0.5941 of 5 stars$9.25-4.3%N/A+12.3%$31.13MN/A-1.592Short Interest ↑OSTXOS Therapies2.0196 of 5 stars$1.43+2.1%$18.00+1,158.7%N/A$30.98MN/A0.00N/AALGSAligos Therapeutics4.0371 of 5 stars$5.05-15.1%$70.00+1,286.1%-81.6%$30.88M$3.95M-0.3890Positive NewsHigh Trading VolumeNRXPNRx Pharmaceuticals2.036 of 5 stars$1.81+1.1%$28.25+1,460.8%-60.4%$30.62MN/A-0.852Short Interest ↑MRNSMarinus Pharmaceuticals2.0745 of 5 stars$0.55-0.2%$4.79+771.6%-92.7%$30.32M$30.99M-0.22110LTRNLantern Pharma2.1995 of 5 stars$2.81-6.0%$25.00+789.7%-44.8%$30.31MN/A-1.5820Positive NewsLVTXLAVA Therapeutics2.4479 of 5 stars$1.14-1.7%$3.17+177.8%-62.9%$29.99M$11.98M-1.1160Short Interest ↓Gap DownAKTXAkari TherapeuticsN/A$1.10-1.4%N/A-8.0%$29.66MN/A0.009Positive NewsGap UpALXOALX Oncology3.3417 of 5 stars$0.54+3.8%$4.14+673.4%-96.2%$28.58MN/A-0.1840Gap UpALLKAllakos4.4785 of 5 stars$0.32+1.4%$2.00+526.0%-71.1%$28.41MN/A-0.16190Positive News Remove Ads Related Companies and Tools Related Companies COEP Competitors OSTX Competitors ALGS Competitors NRXP Competitors MRNS Competitors LTRN Competitors LVTX Competitors AKTX Competitors ALXO Competitors ALLK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMCB Stock Free PMCB Stock Alerts